You are here:

MS in the Media - 20 November 2020

Published on

On this page

  1. New study for advanced MS
  2. Campaign for fair benefits during the pandemic
  3. Stem cells compared to Lemtrada
  4. DMD use and finances

7 -20 November 2020

These are links to recent news stories about multiple sclerosis that may be of interest to people affected by MS in the UK. The link beneath each item will take you to the original story.

Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.

To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter, or regular email alerts.

New study for advanced MS

A UK study will explore whether Mavenclad can slow progression of upper limb disability in people with advanced MS. People with mobility problems are usually excluded from trials, which tend to focus on walking ability. The ChariotMS study will recruit 200 people at centres around the UK. People who think they might be eligible should talk to their neurologist or MS nurse about a possible referral.

Source: Daily Mail
Source: National MS Society (USA)

MS Trust link: Mavenclad (cladribine)

Campaign for fair benefits during the pandemic

The Disability Benefits Consortium - an umbrella group of more than 100 charities - is calling for equality for people who have not yet been moved to Universal Credit. People who get Universal Credit, which combines several previously separate benefits, have been receiving an extra £20 per week during the pandemic. People who are still receiving the individual benefits haven't had this support.

Source: Independent

MS Trust link: Benefits

Stem cells compared to Lemtrada

More people treated with stem cells (AHSCT) showed no signs of disease activity (NEDA) than a people treated with Lemtrada, according to a Swedish study. Three years after treatment, almost nine in ten of the AHSCT group showed no new relapses, no new lesions and no progression. In the Lemtrada group the rate was almost four in ten. More comparison studies are currently under way.

Source: MS News Today

MS Trust link: Stem cell treatment
MS Trust link: Lemtrada (alemtuzumab)

DMD use and finances

Delaying starting a disease modifying drug (DMD) was associated with a more rapid drop in earnings or sooner reliance on benefits compared to people who started treatment within two years of onset of MS, according to a Swedish study.

Source: Managed Health Executive

MS Trust link: Disease modifying drugs for relapsing MS

 

Print this page